Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders

This review summarizes and critically evaluates the published approaches and recent trends in sample pre-treatment, as well as both separation and non-separation techniques used for the determination of uric acid (UA) in saliva. UA is the final product of purine nucleotide catabolism in humans. UA c...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 59; no. 5; pp. 797 - 812
Main Authors Vernerová, Andrea, Kujovská Krčmová, Lenka, Melichar, Bohuslav, Švec, František
Format Journal Article
LanguageEnglish
Published Germany De Gruyter 27.04.2021
Walter De Gruyter & Company
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This review summarizes and critically evaluates the published approaches and recent trends in sample pre-treatment, as well as both separation and non-separation techniques used for the determination of uric acid (UA) in saliva. UA is the final product of purine nucleotide catabolism in humans. UA concentrations in biological fluids such as serum, plasma, and urine represent an important biomarker of diseases including gout, hyperuricemia, or disorders associated with oxidative stress. Previous studies reported correlation between UA concentrations detected in saliva and in the blood. The interest in UA has been increasing during the past 20 years from a single publication in 2000 to 34 papers in 2019 according to MEDLINE search using term “uric acid in saliva”. The evaluation of salivary UA levels can contribute to non-invasive diagnosis of many serious diseases. Increased salivary UA concentration is associated with cancer, HIV, gout, and hypertension. In contrast, low UA levels are associated with Alzheimer disease, progression of multiple sclerosis, and mild cognitive impairment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1434-6621
1437-4331
DOI:10.1515/cclm-2020-1533